COMBINATION THERAPY FOR TREATING CANCER Russian patent published in 2024 - IPC A61K31/5377 A61K31/573 C07D413/12 A61K45/00 A61P35/00 A61P35/02 

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine, namely to methods of treating follicular lymphoma and lymphoma. Method of treating follicular lymphoma involves administering to a subject in need thereof a therapeutically effective dose of compound 44

Compound 44

or a pharmaceutically acceptable salt thereof, a therapeutically effective dose of lenalidomide and a therapeutically effective dose of rituximab; wherein follicular lymphoma is resistant or refractory to at least one previous therapy; and wherein compound 44, said lenalidomide and said rituximab are administered simultaneously or sequentially. Method of treating cancer, where the cancer is lymphoma, involves administering to a subject in need thereof a therapeutically effective dose of compound 44 or a pharmaceutically acceptable salt thereof, a therapeutically effective dose of rituximab and a therapeutically effective dose of lenalidomide; wherein cancer is resistant or refractory to at least one previous therapy; and wherein compound 44, and said rituximab, and said lenalidomide are administered simultaneously or sequentially.

EFFECT: methods described above using compound 44, lenalidomide and rituximab have a synergistic effect in treating lymphoma and follicular lymphoma.

14 cl, 10 dwg, 4 tbl, 7 ex